Anti-inflammatory or anti-SARS-CoV-2 ingredients in Huashi Baidu Decoction and their corresponding targets: Target screening and molecular docking study

被引:4
|
作者
Wang, Zixuan [1 ]
Gao, Hongwei [1 ]
机构
[1] Ludong Univ, Sch Life Sci, Yantai 264025, Shandong, Peoples R China
关键词
COVID-19; Anti-SARS-CoV-2; Anti-inflammatory; Traditional Chinese medicine formula; Target; Active ingredient; COVID-19;
D O I
10.1016/j.arabjc.2023.104663
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Coronavirus disease 2019 (COVID-19) is a rapidly emerging infectious disease caused by SARS-CoV-2. Inflammatory factors may play essential roles in COVID-19 progression. Huashi Baidu Decoction (HSBD) is a traditional Chinese medicine (TCM) formula that can expel cold, dis-pel dampness, and reduce inflammation. HSBD has been widely used for the treatment of COVID-19. However, the active ingredients and potential targets for HSBD to exert anti-inflammatory or anti-SARS-CoV-2 effects remain unclear. In this paper, the active ingredients with anti-inflammatory or anti-viral effects in HSBD and their potential targets were screened using the Dis-covery Studio 2020 software. By overlapping the targets of HSBD and COVID-19, 8 common tar-gets (FYN, SFTPD, P53, RBP4, IL1RN, TTR, SRPK1, and AKT1) were identified. We determined 2 key targets (P53 and AKT1) by network pharmacology. The main active ingredients in HSBD were evaluated using the key targets as receptor proteins for molecular docking. The results sug-gested that the best active ingredients Kaempferol2 and Kaempferol3 have the potential as supple-ments for the treatment of COVID-19. (c) 2023 The Author(s). Published by Elsevier B.V. on behalf of King Saud University. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页数:12
相关论文
共 50 条
  • [31] Establishment of in-house assay for screening of anti-SARS-CoV-2 protein inhibitors
    Emam, Merna H.
    Mahmoud, Mohamed I.
    El-Guendy, Nadia
    Loutfy, Samah A.
    AMB EXPRESS, 2024, 14 (01):
  • [32] Novel, orally available immune modulator MP1032 with pan-variant anti-SARS-CoV-2 and anti-inflammatory activity
    Schumann, S.
    Setz, C.
    Schulz, P.
    Kaiser, A.
    Schubert, U.
    Brysch, W.
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2022, 52 : 176 - 177
  • [33] Control of complement-induced inflammatory responses to SARS-CoV-2 infection by anti-SARS-CoV-2 antibodies
    Bermejo-Jambrina, Marta
    van der Donk, Lieve E. H.
    van Hamme, John L.
    Wilflingseder, Doris
    de Bree, Godelieve
    Prins, Maria
    de Jong, Menno
    Nieuwkerk, Pythia
    van Gils, Marit J.
    Kootstra, Neeltje A.
    Geijtenbeek, Teunis B. H.
    EMBO JOURNAL, 2024, 43 (07): : 1135 - 1163
  • [34] Virtual screening of immunomodulatory medicinal compounds as promising anti-SARS-CoV-2 inhibitors
    Salman, Saad
    Shah, Fahad H.
    Idrees, Jawaria
    Idrees, Fariha
    Velagala, Shreya
    Ali, Johar
    Khan, Abid A.
    FUTURE VIROLOGY, 2020, 15 (05) : 267 - 275
  • [35] Anti-SARS-CoV-2, antioxidant and immunomodulatory potential of dietary flavonol quercetin: Focus on molecular targets and clinical efficacy
    Dinda, Biswanath
    Dinda, Manikarna
    Dinda, Subhajit
    Ghosh, Partha Sarathi
    Das, Saroj Kumar
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY REPORTS, 2024, 10
  • [36] Drug Repurposing for the Identification of Compounds with Anti-SARS-CoV-2 Capability via Multiple Targets
    Yu, Pei-Chen
    Huang, Chen-Hao
    Kuo, Chih-Jung
    Liang, Po-Huang
    Wang, Lily Hui-Ching
    Pan, Max Yu-Chen
    Chang, Sui-Yuan
    Chao, Tai-Ling
    Ieong, Si-Man
    Fang, Jun-Tung
    Huang, Hsuan-Cheng
    Juan, Hsueh-Fen
    PHARMACEUTICS, 2022, 14 (01)
  • [37] A study of anti-SARS-CoV-2 antibody positivity in Duhok City, Iraq
    Hussein, Nawfal R.
    Shahab, Guleer H.
    Rasheed, Narin A.
    Ahmed, Alind N.
    Salih, Reving S.
    Mahdi, Ahmed S.
    Mansour, Sabeeha A.
    Mahdi, Shaveen
    Naqid, Ibrahim A.
    Ibrahim, Nawshan
    Musa, Dildar H.
    Saleem, Zana S. M.
    JOURNAL OF INFECTION IN DEVELOPING COUNTRIES, 2023, 17 (07): : 937 - 943
  • [38] The Impact of Anti-rheumatic Drugs on the Seroprevalence of Anti-SARS-CoV-2 Antibodies in a Cohort of Patients With Inflammatory Arthritis: The MAINSTREAM Study
    Favalli, Ennio Giulio
    Gobbini, Andrea
    Bombaci, Mauro
    Maioli, Gabriella
    Biggioggero, Martina
    Pesce, Elisa
    Favalli, Andrea
    Martinovic, Martina
    Fabbris, Tanya
    Marchisio, Edoardo
    Bandiera, Alessandra
    Gori, Andrea
    Abrignani, Sergio
    Grifantini, Renata
    Caporali, Roberto
    FRONTIERS IN MEDICINE, 2022, 9
  • [39] Asymptomatic individuals positive for anti-SARS-CoV-2 antibodies negative on molecular swab
    Antonelli, Guido
    Anastasi, Emanuela
    Ciprani, Fabrizio
    Cabral, Rodolfo J. Riveros
    Ialongo, Cristiano
    Capobianchi, Maria R.
    Turriziani, Ombretta
    Angeloni, Antonio
    LANCET MICROBE, 2021, 2 (05): : E178 - E178
  • [40] New Diclofenac Derivatives as Anti-Microbial, Anti-Inflammatory Agents: Design, Synthesis, Biological Screening, and Molecular Docking Study
    Adel M. Kamal Mahmoud M. Hamed
    Shawkat A. El-Dean
    Mahmoud S. Abdel-Mohsen
    Russian Journal of Bioorganic Chemistry, 2021, 47 : 208 - 220